Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

[1]  R. Claus,et al.  Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting , 2010, Bone Marrow Transplantation.

[2]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Ehninger,et al.  Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil , 2010, Annals of Hematology.

[4]  H. Kantarjian,et al.  Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Gobbi,et al.  Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes , 2009, Clinical Cancer Research.

[6]  U. Germing,et al.  Impact on survival of different treatments for myelodysplastic syndromes (MDS). , 2009, Leukemia research.

[7]  H. Kantarjian,et al.  Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia , 2009, Cancer.

[8]  J. Hainsworth,et al.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[10]  K. Götze,et al.  A limited number of 5-azacitidine cycles can be effective treatment in MDS , 2009, Annals of Hematology.

[11]  A. Kiani,et al.  5–azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation. , 2008 .

[12]  J. Gabrilove,et al.  A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium , 2008 .

[13]  M. Lübbert,et al.  Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups , 2008 .

[14]  J. Maciejewski,et al.  Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) , 2008 .

[15]  G. Mufti,et al.  The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) , 2008 .

[16]  J. Issa,et al.  Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy , 2008 .

[17]  Hee-Jin Kim,et al.  Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification‐Based Prognostic Scoring System (WPSS) and comparison with IPSS , 2008, European journal of haematology.

[18]  F. Lyko,et al.  Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.

[19]  N. Howlader,et al.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.

[20]  Rainer Haas,et al.  Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes , 2008, Annals of Hematology.

[21]  G. Mufti,et al.  Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS) , 2008 .

[22]  D. Haase.  Cytogenetic features in myelodysplastic syndromes , 2008, Annals of Hematology.

[23]  J. Issa,et al.  Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine , 2008, Leukemia & lymphoma.

[24]  G. Mufti,et al.  PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA) , 2008 .

[25]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[26]  G. Mufti,et al.  Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine. , 2007 .

[27]  Jorge Cortes,et al.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.

[28]  G. Mufti,et al.  CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine , 2007, Leukemia.

[29]  R. Claus,et al.  Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. , 2007, Blood.

[30]  U. Germing,et al.  Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.

[31]  G. Kobbe,et al.  Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. , 2007, Leukemia research.

[32]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[34]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[35]  C. Steidl,et al.  The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.

[36]  M. Lübbert,et al.  In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies , 2005, Annals of Hematology.

[37]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Richard Pazdur,et al.  FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. , 2005, The oncologist.

[39]  G. Mufti,et al.  Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. , 2004, Blood.

[40]  D. Christiansen,et al.  Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia , 2003, Leukemia.

[41]  N. Kröger,et al.  Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia , 2003, Annals of Hematology.

[42]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[43]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Holland,et al.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Hagemeijer,et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.

[46]  Keith D Robertson,et al.  DNA methylation, methyltransferases, and cancer , 2001, Oncogene.

[47]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[48]  U. Germing,et al.  Long‐term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis , 2000, British journal of haematology.

[49]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[50]  R. Willers,et al.  Remission Rates, Survival, and Prognostic Factors in Ninety Patients with Advanced Myelodysplastic Syndromes Treated with Intensive Chemotherapy , 1997 .